Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Glomerulosclerosis, Focal Segmental

• AMPK-activation by Metformin in FSGS: AMP-FSGS
• A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment
• Efficacy and Safety of VB119 in Subjects With Minimal Change Disease and Focal Segmental Glomerulosclerosis
• Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
• A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis
• Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
• Obinutuzumab in Primary FSGS
• Atrasentan in Patients With Proteinuric Glomerular Diseases
• A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
• Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
• Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
• PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
• A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
• Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan
• Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
• A Study of CCX140-B in Subjects With FSGS
• Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
• A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
• FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
• A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
• Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
• Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
• Valproic Acid for Idiopathic Nephrotic Syndrome
• Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
• Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
• Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
• Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
• A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
• A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
• Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
• The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis
• Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
• Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
• Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
• Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)
• Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis
• Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
• Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor
• Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
• Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis
• Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
• Rituximab Treatment of Focal Segmental Glomerulosclerosis
• Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental
• Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis
• Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)
• Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)
• Podocyte Retinoids
• Sirolimus for Focal Segmental Glomerulosclerosis
• Permeability Factor in Focal Segmental Glomerulosclerosis
• Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
• Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)